Eric Escobar

Ph.D.

Vice President of Research & Development

Bowen's FX Therapeutics

Eric joined Zymeworks as Protein Engineer in 2010, and developed technologies used in therapeutics to fight cancer. Internally, he worked on several programs including the development of Zanidatamab, while externally he led partnerships of Zymeworks with companies such as GSK for the development of other novel technology platforms and therapeutics. After success at Zymeworks, in 2022, Eric became a consultant for various biotechnology companies, supporting the research and development of novel protein therapeutics in many applications. In 2024, Eric joined Bowen’s FX Therapeutics as Vice President of Research and Development. He is using his expertise to optimize proteins that can serve as protein replacement therapies for people affected with Fragile X Syndrome. His goal is to make viable therapeutics for Bowen and all people touched by this condition. https://www.bowensfx.com/